An Integrated Multi-omics Study on the Molecular Mechanisms of Ureteral Stricture (US-MOP)

February 7, 2026 updated by: Gang Chen, First Affiliated Hospital of Chongqing Medical University

The goal of this observational study is to investigate the systemic pathogenesis and identify potential diagnostic biomarkers in patients with ureteral stricture and healthy volunteers. The main questions it aims to answer are:

What are the systemic differences in the gut microbiome, urine microbiome, and metabolomic profiles (fecal, urinary, and serum) between patients with ureteral stricture and healthy controls? What are the correlations between these microbial/metabolic alterations and clinical phenotypes, such as stricture severity, inflammatory levels, and renal function? Researchers will compare the biological panoramic profiles of patients with ureteral stricture to those of healthy controls to see if specific "microbiome-metabolite-disease" regulatory networks drive the development of the condition.

Participants will:

Provide stool samples for gut microbiome (16S/Metagenomics) and metabolomic analysis.

Provide urine samples for urine microbiome and metabolomic analysis. Provide blood (serum) samples for systemic metabolomic profiling. Undergo clinical assessments, including medical history collection, imaging (e.g., CT/IVP), and laboratory tests (e.g., renal function, inflammatory markers) to evaluate disease severity.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

Background and Scientific Rationale Ureteral stricture is a major urological challenge that leads to urinary tract obstruction and progressive renal impairment. While its etiology is diverse-ranging from iatrogenic injury to congenital anomalies-the underlying molecular mechanisms, particularly in inflammatory and idiopathic cases, remain poorly understood. Current surgical interventions carry a risk of recurrence, underscoring the urgent need to identify systemic biomarkers and novel therapeutic targets.

The Gut-Kidney Axis and Urinary Microbiome Recent advances have highlighted the "gut-kidney axis," where the gut microbiota and its metabolites modulate distant organ pathology through immune regulation and metabolic signaling. Furthermore, the discovery of a unique urinary microbiome has challenged the traditional view of urinary sterility, suggesting that local dysbiosis may contribute to urological diseases. Metabolites, serving as the functional intermediaries between the microbiome and the host phenotype, provide a critical bridge to understanding these complex interactions.

Integrated Multi-omics Strategy

This study adopts an innovative integrated multi-omics approach to characterize the biological landscape of ureteral stricture across three compartments: the intestine, the urinary tract, and the systemic circulation. By combining high-throughput sequencing of gut and urine microbiomes with mass spectrometry-based metabolomic profiling (fecal, urinary, and serum), we aim to:

Map Systemic Dysbiosis: Identify specific microbial taxa and metabolic signatures that distinguish patients with ureteral stricture from healthy individuals.

Elucidate Regulatory Networks: Construct "microbiome-metabolite-disease" networks to explore how microbial alterations correlate with clinical phenotypes, such as fibrosis markers, inflammatory levels, and renal function indicators.

Identify Functional Pathways: Utilize functional enrichment analysis to pinpoint metabolic pathways (e.g., those related to inflammation or tissue fibrosis) that are modulated by the microbiota.

Clinical Significance The ultimate goal of this research is to provide a systemic biological perspective on the pathogenesis of ureteral stricture. By integrating cross-platform data, we expect to identify high-sensitivity non-invasive biomarkers for early diagnosis and provide a theoretical foundation for future microecology-targeted interventions.

Study Type

Observational

Enrollment (Estimated)

120

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
      • Chongqing, China, 400016
        • Department of Urology, The First Affiliated Hospital of Chongqing Medical University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

The study population consists of adult patients diagnosed with ureteral stricture who are seeking medical consultation or surgical treatment at the Department of Urology in a tertiary medical center The First Affiliated Hospital of Chongqing Medical University. These patients represent a diverse range of etiologies, including iatrogenic, inflammatory, and idiopathic narrowing.

Simultaneously, a cohort of healthy volunteers will be recruited from the hospital's physical examination center or the local community to serve as the control group. These volunteers are age- and sex-matched to the patient group and share a similar geographic and dietary background to minimize environmental confounding factors in microbiome and metabolomic analysis.

Description

Inclusion Criteria (Ureteral Stricture Group):

Age between 18 and 75 years, regardless of gender. Diagnosis of ureteral stricture confirmed by clinical symptoms and imaging (e.g., CT, IVP, or retrograde pyelography) or ureteroscopy.

The patient is scheduled for or undergoing standard clinical evaluation/treatment for ureteral stricture.

Willingness to provide stool, urine, and blood samples. Informed consent signed by the participant or their legal representative.

Inclusion Criteria (Healthy Control Group):

Age- and sex-matched volunteers (18-75 years). No history of ureteral stricture, urinary tract obstruction, or significant renal disease.

Physical examination and laboratory tests (renal function, routine urine analysis) are within normal limits.

Exclusion Criteria (Applicable to Both Groups):

Use of antibiotics, probiotics, prebiotics, or antifungal medications within the 4 weeks prior to sample collection.

History of chronic gastrointestinal diseases (e.g., Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), or chronic diarrhea).

Known malignant tumors of the urinary tract or other systemic malignancies. History of major abdominal or urinary tract surgery within the last 3 months (excluding the current planned procedure for patients).

Presence of severe systemic diseases, including uncontrolled diabetes, severe hepatic dysfunction, or end-stage heart failure.

Pregnancy or breastfeeding. Any other condition that, in the opinion of the investigator, may interfere with the microbiome or metabolomic analysis.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Ureteral Stricture Group
Patients diagnosed with ureteral stricture through clinical symptoms, imaging (e.g., CT, IVP, or retrograde pyelography), or endoscopic evaluation. This cohort includes individuals with iatrogenic, inflammatory, or idiopathic strictures. Intervention of interest: Participants will undergo biological sample collection, including fecal samples for gut microbiome and metabolome analysis, mid-stream urine for urinary microbiome and metabolome analysis, and fasting blood samples for systemic serum metabolomic profiling. Clinical data such as renal function and stricture characteristics will also be recorded.
Healthy Control Group
Age- and sex-matched healthy volunteers with no history of ureteral stricture, urinary tract obstruction, or significant renal diseases. Candidates with recent (within 3 months) use of antibiotics or probiotics, or those with chronic gastrointestinal or metabolic disorders, are excluded. Intervention of interest: This cohort will provide identical biological samples (fecal, urine, and blood) following the same protocols as the patient group to establish a baseline for comparative multi-omics analysis.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Differences in Gut and Urinary Microbiome Composition
Time Frame: Baseline (at the time of sample collection, within 1 week of enrollment)
Comparison of microbial diversity and taxonomic composition between ureteral stricture patients and healthy controls. Metrics include Alpha-diversity (e.g., Shannon Index), Beta-diversity (e.g., PCoA based on Bray-Curtis distance), and relative abundance of specific microbial taxa from Phylum to Genus levels using 16S rRNA or metagenomic sequencing.
Baseline (at the time of sample collection, within 1 week of enrollment)
Differential Metabolomic Profiles in Fecal, Urinary, and Serum Samples
Time Frame: Baseline (at the time of sample collection, within 1 week of enrollment)
Identification of significantly different metabolites between the two groups. Parameters include the concentration and relative intensity of metabolites identified via LC-MS/MS or GC-MS. Significant metabolites will be screened based on Variable Importance in Projection (VIP) > 1.0 and p-value < 0.05 from multivariate and univariate statistical analyses.
Baseline (at the time of sample collection, within 1 week of enrollment)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

First Affiliated Hospital of Chongqing Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

February 1, 2026

Primary Completion (Estimated)

June 30, 2026

Study Completion (Estimated)

July 31, 2026

Study Registration Dates

First Submitted

February 7, 2026

First Submitted That Met QC Criteria

February 7, 2026

First Posted (Actual)

February 13, 2026

Study Record Updates

Last Update Posted (Actual)

February 13, 2026

Last Update Submitted That Met QC Criteria

February 7, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • US-MOP202517401

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

The decision to share individual participant data (IPD) is currently under evaluation. The investigators will finalize the data sharing plan after reviewing the institutional data management policies and ensuring that all sharing protocols strictly adhere to participant privacy and ethical guidelines. A final determination will be made at the time of publication.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Ureteral Obstruction

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe